Ang Lifesciences India Ltd. · BSE:ANG
Ang Lifesciences India — IPO Roadshow (August 2017)
17 slides from Ang Lifesciences India's IPO roadshow presentation, August 2017
Slide 1: Investors Presentation
rN Investors 1, Lee Presentation \4. ’ WN GUINESS Redefini S/H
Slide 2: Disclaimer
The presentation has been prepared by Guiness Securities Limited for “ANG Lifesciences India Ltd.” (“Company”) in context of forthcoming Initial Public Offer (IPO) of the company. In preparing this document, we have relied upon and assumed, without any independent verification, the accuracy and comp
Slide 3: Company Info
ANG Lifesciences India Limited, incorporated in the year 2006, is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of Company Info sterile dry powder injection vials. Registered Office :- Darbara Complex, SCO 113, First Floor, District S
Slide 4: Products, marketing network and R&D
The Company’s products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anaesthetic. The Company always aims to offer quality products to it’s customers. It adopts quality checks to ensure the adherence to desired specificat
Slide 5: Promoters and management
Mr. Rajesh Gupta, aged 46 years, is the Promoter and Managing Director of our Company. He has obtained degree of Civil Engineering from Thaper Institute of Engineering and Technology, Patiala in the year 1993. Initially he started his career with the construction business and he embarked his career
Slide 6: The Product Line
The Product line Includes :- Dry Powder Injectibles for Anti-Biotics Anti-Ulcerant Glucocorticoid Anti-Inflammatory Anti-Malarial Anesthetic Guiness Securities Limited
Slide 7: Key strengths
Experienced Promoters and management team High standard Manufacturing process Quality Assurance and Standards Strong Marketing capability Cordial relationship with Customers, suppliers & employees Focus on Research and Development (R & D) Expansion plans to PAN India and International
Slide 8: Installed capacity and capacity utilisation
EXISTING PROPOSED PARTICULARS 2014-15 2015-16 2016-17 2017-18 2018-19 2019-20 Installed Capacity (Pieces in Lakhs) 700.00 700.00 700.00 700.00 700.00 700.00 Capacity Utilisation 268.95 470.75 507.68 630.15 644.00 664.00 Capacity Utilisation (%) 38% 67% 73% 90% 92% 95% Manufacturing unit spread over
Slide 9: Expansion to PAN India and international markets
The Company plans to expand it’s presence in PAN India as well as International Market Guiness Securities Limited
Slide 10: Financial Reports
aS GUINESS as FINANCIAL REPORTS Bi sis Guiness Securities Limited
Slide 11: Statement of Balance Sheet
Statement Of Balance Sheet As at March 31 (Rs in Lakhs) Particulars 2013 2014 2015 2016 2017 EQUITY AND LIABILITIES 1. Shareholders’ Funds a. Share Capital 368.25 368.25 368.25 368.25 368.25 b. Reserves & Surplus (141.32) (97.03) (56.67) 108.81 390.80 2. Non Current Liabilities a. Long Term Borrowin
Slide 12: Statement of Profit and Loss
For the period ended March 31, (Rs in Lakhs) Particulars 2013 2014 2015 2016 2017 INCOME Revenue from Operations 1,624.91 3,449.93 3,684.16 5,492.30 6,766.81 Other Income 3.73 11.96 9.46 21.03 25.02 Total Income (A) 1,628.64 3,461.89 3,693.63 5,513.32 6,791.82 EXPENDITURE Cost of Material Consumed 1
Slide 13: Key financial ratios
For the period ended March 31, Particulars 2013 2014 2015 2016 2017 Restated PAT as per P& L Account (6.21) 19.29 40.4 165.48 292 Number of Equity Shares outstanding at the end of the 36.83 36.83 36.83 36.83 36.83 Year Net Worth 226.93 271.22 311.58 477.06 759.05 Earnings Per Share Basic & Diluted (
Slide 14: Total Income and Net Worth
Total Income (A) Net Worth 8,000.00 800 759.05 7,000.00 6,791.82 700 6,000.00 600 5,513.32 5,000.00 500 477.06 4,000.00 400 3,461.89 3,693.63 Total Income (A) Net Worth 3,000.00 300 311.58 271.22 2,000.00 200 226.93 1,628.64 1,000.00 100 - 0 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 The reve
Slide 15: Peer comparison
REVENUE PAT MKT CAP** Particulars for year ended 31/3/17 EPS PE Ratio* RONW NAV (in Cr) (in Cr) (in Cr) Kwality Pharmaceuticals Ltd (Standalone) 51.48 1.93 6.63 13.42 13.41 49.42 42.02 Bliss GVS Pharma Limited (Standalone) 370.78 62.60 6.07 26.99 12.74 47.63 1724.10 Caplin Point Laboratories Limited
Slide 16: Objects of the issue and issue details
• To meet the working capital requirement of the Company Particulars Details • Issue Expenses Issue Open 29 AUGUST 2017 Issue Close 31 AUGUST 2017 Besides the above mentioned prime objective of the Issue Type FIXED PRICE issue, the company also seeks to achieve the benefits of listing on the SME pla
Slide 17: Thank you
Bs AIGUINESS Thank yo A Guiness Securities Limited JKIGUINESS Redefining Services